Determining the minimally clinically important difference for the pediatric liver transplant quality of life questionnaire
Journal of Pediatric Gastroenterology and Nutrition · 2024
DOI: 10.1002/jpn3.12256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Simone Kortbeek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Liver Transplantation, Quality of Life, Minimal Clinically Important Difference, Patient Reported Outcome Measures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: None, Canadian Association for Study of the Liver-Canadian Liver Foundation (CASL-CLF) Clinical Hepatology Fellowship.
Abstract (Originalsprache)
Purpose
The Pediatric Liver Transplant Quality of Life (PeLTQL) questionnaire is a disease‐specific patient reported outcome measure for pediatric liver transplant (LT) recipients. To‐date, threshold values above which a change in PeLTQL score is considered meaningful to patients are unavailable. This study proposes the first values for the minimally clinically important difference (MCID) for the PeLTQL.
Methods
In this retrospective cohort study, anchor and distribution‐based methods were used to estimate the MCID for the PeLTQL. Questionnaires completed between March 2013, and July 2022 were included if data from two sequential visits were available. An internal anchor question was used for anchor‐based determination of the MCID. A final MCID estimate was ascertained from triangulation of all methods.
Results
PeLTQL data from 65 LT recipients (26 [40%] male, 17 [42%] biliary atresia, median age at LT 3.08 years [interquartile range 0.99–7.30]), and their caregivers were included for analysis. Median patient age at time of baseline PeLTQL completion was 13.84 (10.90–15.86) years. The MCID for self‐PeLTQL total scores ranged from 4.53 to 8.46, and from 4.47 to 8.85 for proxy responses. By triangulation, the MCID of the PeLTQL total score was 6.45 and 6.78 for self and proxy responses respectively.
Conclusion
A change in PeLTQL score of 6.5 or more points suggests a change in health status that is meaningful to the patient, providing the clinical team an opportunity to engage the patient's voice in reassessing current health status and management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
- Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- Transplant and Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID-Profile: Simone Kortbeek, Vicky L Ng
Förderung
- None
- Canadian Association for Study of the Liver-Canadian Liver Foundation (CASL-CLF) Clinical Hepatology Fellowship
Zitieren
APA
Kortbeek, S., Johara, F. T., Kwan, K., John, T., & Ng, V. L. (2024). Determining the minimally clinically important difference for the pediatric liver transplant quality of life questionnaire. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12256
Vancouver
Kortbeek S, Johara FT, Kwan K, John T, Ng VL. Determining the minimally clinically important difference for the pediatric liver transplant quality of life questionnaire. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12256
BibTeX
@article{Kortbeek2024,
author = {Kortbeek, Simone and Johara, Fatema T and Kwan, Karina and John, Tomisin and Ng, Vicky L},
title = {Determining the minimally clinically important difference for the pediatric liver transplant quality of life questionnaire},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
doi = {10.1002/jpn3.12256}
}
EUVIMED